Aligos Therapeutics
Develops liver- and viral-disease drug candidates, including a chronic hepatitis B program.
$7.02
After-hours close+0.17 (+2.48%)
At close$6.85(−3.11%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 44.84%Insiders —
Shares outstanding 6.19M · Float 4.80M · 77.5% free float
Insiders — no current Form 4 position.
Institutions13F, as of Mar 31, 2026
34 holders · 2.78M shares · 6 new positions · 14 increased · 9 reduced · 11 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Deep Track Capital, LP | 444.1K | 7.18% | 0 | May 15, 2026 |
| Alyeska Investment Group, L.P. | 412.0K | 6.66% | 0 | May 15, 2026 |
| Sio Capital Management, LLC | 327.2K | 5.29% | −8.7K | May 14, 2026 |
| Marshall Wace, LLP | 267.1K | 4.32% | −1.5K | May 15, 2026 |
| Bank of America Corp /DE/ | 229.8K | 3.71% | +216.6K | May 18, 2026 |
| Vanguard Capital Management LLC | 178.3K | 2.88% | +178.3Knew | May 15, 2026 |
| Woodline Partners LP | 177.4K | 2.87% | −111.8K | May 15, 2026 |
| Summittx Capital, L.P. | 148.8K | 2.40% | +9.4K | May 15, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Alyeska Investment Group, L.P. | 9.99% | 530.0K | 13G | May 15, 2025 ↗ |
| Adage Capital Management, L.P.incl. Robert Atchinson, Phillip Gross | 7.12% | 218.8K | 13G | Nov 12, 2024 ↗ |
| Lawrence M. Blatt | 5.60% | 316.2K | 13D | Jun 24, 2026 ↗ |
| Sio Capital Management, LLC | 5.46% | 335.9K | 13G | Feb 11, 2026 ↗ |
InsidersForm 4
No current Form 4 position on record.
4 ten-percent owners hold 601.4K shares by Form 4, outside the officers-and-directors figure above · 10 people have not refiled in the last 18 months (565.6K shares), so they are not in the figure above
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.